At a glance
- Originator Merck & Co
- Class Class III antiarrhythmics
- Mechanism of Action Potassium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Arrhythmias
Most Recent Events
- 02 Aug 2006 Discontinued for Arrhythmias in Switzerland (PO)
- 02 Aug 2006 Discontinued for Arrhythmias in USA (PO)
- 12 Jan 2001 No-Development-Reported for Arrhythmias in Switzerland (PO)